Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Patient advocates are pushing FDA to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.

You may also be interested in...



Disease-Of-The-Quarter Club: FDA Plans 20 Patient Network Meetings Over Five Years

PDUFA V framework to involve patients in the creation of the risk-benefit criteria for various diseases kicks off before the legislation is even enacted.

BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals

Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.

Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial

Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.

Topics

Related Companies

UsernamePublicRestriction

Register

PS005894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel